Finch Therapeutics Group Inc


Prices are adjusted according to historical splits.

Finch Therapeutics Group Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$10.22 million
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Finch Therapeutics Group Inc had its IPO on 2021-03-19 under the ticker symbol FNCH.

The company operates in the Healthcare sector and Biotechnology industry. Finch Therapeutics Group Inc has a staff strength of 18 employees.

Stock update

Shares of Finch Therapeutics Group Inc opened at $6.19 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $6 - $6.46, and closed at $6.13.

This is a -2.54% slip from the previous day's closing price.

A total volume of 5,336 shares were traded at the close of the day’s session.

In the last one week, shares of Finch Therapeutics Group Inc have slipped by -2.85%.

Finch Therapeutics Group Inc's Key Ratios

Finch Therapeutics Group Inc has a market cap of $10.22 million, indicating a price to book ratio of 0.3623 and a price to sales ratio of 23.383.

In the last 12-months Finch Therapeutics Group Inc’s revenue was $253000 with a gross profit of $-57032000 and an EBITDA of $-70163000. The EBITDA ratio measures Finch Therapeutics Group Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Finch Therapeutics Group Inc’s operating margin was -29407.12% while its return on assets stood at -31.51% with a return of equity of -146.19%.

In Q2, Finch Therapeutics Group Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 69.8%.

Finch Therapeutics Group Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-85.65 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Finch Therapeutics Group Inc’s profitability.

Finch Therapeutics Group Inc stock is trading at a EV to sales ratio of 6.5371 and a EV to EBITDA ratio of -0.1324. Its price to sales ratio in the trailing 12-months stood at 23.383.

Finch Therapeutics Group Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$66.86 million
Total Liabilities
$9.58 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Finch Therapeutics Group Inc ended 2023 with $66.86 million in total assets and $0 in total liabilities. Its intangible assets were valued at $66.86 million while shareholder equity stood at $27.89 million.

Finch Therapeutics Group Inc ended 2023 with $0 in deferred long-term liabilities, $9.58 million in other current liabilities, 2000.00 in common stock, $-344938000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $34.05 million and cash and short-term investments were $34.05 million. The company’s total short-term debt was $1,656,000 while long-term debt stood at $0.

Finch Therapeutics Group Inc’s total current assets stands at $36.50 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0.00 compared to accounts payable of $432000.00 and inventory worth $0.

In 2023, Finch Therapeutics Group Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Finch Therapeutics Group Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Finch Therapeutics Group Inc stock is currently trading at $6.13 per share. It touched a 52-week high of $86.7 and a 52-week low of $86.7. Analysts tracking the stock have a 12-month average target price of $150.

Its 50-day moving average was $7.57 and 200-day moving average was $12.08 The short ratio stood at 2.19 indicating a short percent outstanding of 0%.

Around 5088.1% of the company’s stock are held by insiders while 1979.2% are held by institutions.

Frequently Asked Questions About Finch Therapeutics Group Inc

The stock symbol (also called stock or share ticker) of Finch Therapeutics Group Inc is FNCH

The IPO of Finch Therapeutics Group Inc took place on 2021-03-19

Similar Industry Stocks (Biotechnology)

Last Price

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.


200 Inner Belt Road, Somerville, MA, United States, 02143